The IMMUTOL Consortium, led by Silvia Gregori (San Raffaele Telethon Institute for Gene Therapy– SR-TIGET) successfully kicked-off the project at a hybrid event, held at the Fondazione Telethon, Milano (Italy), between 24th and 25th of May.
Thanks to EU Horizon Europe (Grant Agreement Nr.: 101080562) for supporting fast-tracking the development and validation of an Advanced Therapy Medicinal Product based on engineered dendritic cells to treat patients with immune-mediated diseases with an unmet medical need, in particular multiple sclerosis.